This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

    More

    Page   1/1   
  • Shaping the Future: From Meaningful Use to Meaningful User
    With the recent release of Meaningful Use Stage 2 requirements, health care providers may feel increasing pressure on their organisations to achieve the stated goals in order to qualify for available incentive dollars.
  • Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Calls for more transparency and disclosure of payments made by the life sciences industry to health care professionals are creating challenges and opportunities for all parties involved in the delivery of health care.
  • The next phase: Opportunities in China's pharmaceuticals market
    As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second largest life sciences and health care market within this decade.
  • R&D value measurement: Is R&D earning its investment?
    Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement to learn more about how pharmaceutical innovation is facing a fundamental productivity challenge.
  • Pharmacovigilance: Alert and on guard
    Over the past decade, a series of adverse drug safety-related events have led to increased scrutiny and drug safety monitoring regulations. The business case for building strong, efficient pharmacovigilance organisations has never been better.
  • Value-based Pricing for Pharmaceuticals
    In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialisation and pricing. This Issue Brief summarises what is known to date about value-based pricing and identifies opportunities for additional exploration.
    • Page   1/1   
Stay connected:

Material on this website is © 2013 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See Legal for copyright and other legal information.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.

More on Deloitte
Learn about our site